Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$41.27 - $98.62 $12,381 - $29,586
300 New
300 $14,000
Q3 2019

Oct 18, 2019

SELL
$77.91 - $109.6 $54,537 - $76,720
-700 Closed
0 $0
Q2 2019

Jul 16, 2019

BUY
$59.49 - $104.71 $41,643 - $73,297
700 New
700 $7.27 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Clear Street Markets LLC Portfolio

Follow Clear Street Markets LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clear Street Markets LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clear Street Markets LLC with notifications on news.